PMID- 19096145
OWN - NLM
STAT- MEDLINE
DCOM- 20090205
LR  - 20211020
IS  - 1875-8606 (Electronic)
IS  - 1570-5870 (Print)
IS  - 1570-5870 (Linking)
VI  - 31
IP  - 1
DP  - 2009
TI  - HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent 
      probe amplification in comparison with immunohistochemistry and in situ 
      hybridization.
PG  - 1-10
AB  - BACKGROUND: Assessment of HER-2/neu status in invasive breast cancer is crucial 
      to establish eligibility for trastuzumab and taxane based chemotherapy. Next to 
      immunohistochemistry (IHC) to evaluate protein overexpression, a second line gene 
      amplification test is required for cases with equivocal protein expression. This 
      study aimed to validate a new PCR based test, called Multiplex Ligation-dependent 
      Probe Amplification (MLPA), as a simple and quick method to assess HER-2/neu gene 
      amplification status in invasive breast cancer. METHODS: MPLA results were 
      compared with gene amplification status assessed by fluorescence in situ 
      hybridization (FISH) and chromogenic in situ hybridization (CISH) as gold 
      standard, and with protein overexpression by IHC in 518 breast carcinoma 
      patients. RESULTS: About 10% of cases overexpressed HER-2/neu at the protein 
      level (IHC), and 11% of cases showed gene-amplification by MLPA. A high 
      concordance was found between FISH and CISH, MLPA and IHC, and MLPA and CISH. 
      MLPA showed amplification in 7/36 (19%) of the equivocal IHC 2+ cases. However, 
      of the IHC 0/1+ cases, 6/434 (1.4%) were also amplified by MLPA, and 
      amplification was confirmed in all of these cases by FISH/CISH. On the other 
      hand, one of the 48 (2%) IHC 3+ cases was normal by MLPA and lack of 
      amplification was confirmed by FISH/CISH. CONCLUSION: MLPA is a fast, accurate 
      and cheap method to detect breast cancer HER-2/neu amplification in small 
      quantities of DNA extracted from paraffin blocks, and thereby a reliable 
      alternative to FISH and CISH.
FAU - Moelans, Cathy B
AU  - Moelans CB
AD  - Department of Pathology, University Medical Centre Utrecht, Heidelberglaan 100, 
      Utrecht, The Netherlands.
FAU - de Weger, Roel A
AU  - de Weger RA
FAU - van Blokland, Marja T M
AU  - van Blokland MT
FAU - Ezendam, Chantal
AU  - Ezendam C
FAU - Elshof, Sabrina
AU  - Elshof S
FAU - Tilanus, Marcel G J
AU  - Tilanus MG
FAU - van Diest, Paul J
AU  - van Diest PJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Netherlands
TA  - Cell Oncol
JT  - Cellular oncology : the official journal of the International Society for 
      Cellular Oncology
JID - 101219418
RN  - 0 (Molecular Probes)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
CIN - Cell Oncol. 2010 Jan 1;32(4):311-2. PMID: 20442492
MH  - Breast Neoplasms/*genetics/metabolism
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Ligase Chain Reaction/economics/*methods
MH  - Molecular Probes/genetics
MH  - Receptor, ErbB-2/*genetics/metabolism
PMC - PMC4618800
EDAT- 2008/12/20 09:00
MHDA- 2009/02/06 09:00
PMCR- 2008/12/18
CRDT- 2008/12/20 09:00
PHST- 2008/12/20 09:00 [entrez]
PHST- 2008/12/20 09:00 [pubmed]
PHST- 2009/02/06 09:00 [medline]
PHST- 2008/12/18 00:00 [pmc-release]
AID - 615178 [pii]
AID - 10.3233/clo-2009-0461 [doi]
PST - ppublish
SO  - Cell Oncol. 2009;31(1):1-10. doi: 10.3233/clo-2009-0461.